Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

whole-body pet scanner add-on device presented at #SNMMI 2023

New PET technology offers 'clear improvement' of whole-body scan resolution

The new technology achieves this by way of two add-on detectors that simultaneously scan patients during their whole-body PET exam.

Thumbnail

New prostate cancer PET imaging agent officially available for commercial use

Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

folate-based radiopharmaceuticals

Folate-based radiopharmaceuticals could improve detection of gliomas

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.

brain money alzheimer dementia

Will PET imaging be covered alongside new Alzheimer's drugs? CMS dodges topic in new coverage decision

The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.

Two examples of PSMA-PET scans showing numerous prostate cancer metastases spread throughout the body. Many of these smaller tumors would not have been dected on previous standard-of-care imaging. Photo on left courtesy of SNMMI, right University of Chicago. #PSMAPET

PSMA-PET a more cost-effective option for patients long-term compared to standard prostate imaging

The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.

Thumbnail

Radioactive substances unnecessary in new method for measuring brain glucose metabolism

Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.

Thumbnail

Accessibility, reimbursement and other issues limit uptake of PET/CT among oncologists, survey reveals

Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.

Thumbnail

Experts release new appropriate use criteria for lymphoscintigraphy in sentinel node mapping

The AUC includes a total of 32 clinical scenarios that have been grouped into four categories of cancer: breast, skin, cancer of other sites and lymphedema.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.